These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24794698)

  • 1. Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer.
    Coory M; Lamb KE; Sorich M
    J Clin Epidemiol; 2014 Sep; 67(9):966-72. PubMed ID: 24794698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients.
    van Laar C; van der Sangen MJ; Poortmans PM; Nieuwenhuijzen GA; Roukema JA; Roumen RM; Tjan-Heijnen VC; Voogd AC
    Eur J Cancer; 2013 Oct; 49(15):3093-101. PubMed ID: 23800672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
    Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
    Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
    Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
    J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Provincial Breast Disease Site Group.
    Whelan TJ; Lada BM; Laukkanen E; Perera FE; Shelley WE; Levine MN
    Cancer Prev Control; 1997 Aug; 1(3):228-40. PubMed ID: 9765748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy.
    Lin PH; Yeh MH; Liu LC; Chen CJ; Tsui YC; Su CH; Wang HC; Liang JA; Chang HW; Wu HS; Yeh SP; Li LY; Chiu CF
    J Surg Oncol; 2013 Nov; 108(6):352-7. PubMed ID: 23996583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence.
    Houssami N; Turner R; Macaskill P; Turnbull LW; McCready DR; Tuttle TM; Vapiwala N; Solin LJ
    J Clin Oncol; 2014 Feb; 32(5):392-401. PubMed ID: 24395846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management and outcomes of isolated axillary node recurrence in breast cancer.
    Konkin DE; Tyldesley S; Kennecke H; Speers CH; Olivotto IA; Davis N
    Arch Surg; 2006 Sep; 141(9):867-72; discussion 872-4. PubMed ID: 16983030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
    Komoike Y; Akiyama F; Iino Y; Ikeda T; Akashi-Tanaka S; Ohsumi S; Kusama M; Sano M; Shin E; Suemasu K; Sonoo H; Taguchi T; Nishi T; Nishimura R; Haga S; Mise K; Kinoshita T; Murakami S; Yoshimoto M; Tsukuma H; Inaji H
    Cancer; 2006 Jan; 106(1):35-41. PubMed ID: 16333848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
    Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
    Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies.
    Chia SK; Speers CH; Bryce CJ; Hayes MM; Olivotto IA
    J Clin Oncol; 2004 May; 22(9):1630-7. PubMed ID: 15117985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy.
    Garassino I; Gullo G; Orefice S; Tondulli L; Masci G; Salvini P; Eboli M; Di Tommaso L; Giordano L; Alloisio M; Roncalli M; Santoro A
    Breast; 2009 Aug; 18(4):263-6. PubMed ID: 19682903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
    Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP
    Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico].
    Arce-Salinas C; Lara-Medina FU; Alvarado-Miranda A; Castañeda-Soto N; Bargalló-Rocha E; Ramírez-Ugalde MT; Pérez-Sánchez V; Rivera L; Gambo-Vignole C; Santamaría-Galicia J; Nieves-Casas RI; Morán-Muñoz H; Mohar-Betancourt A
    Rev Invest Clin; 2012; 64(1):9-16. PubMed ID: 22690524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.